Combined cardioprotection in patients with high cardiovascular risk

Sizova Zh.M.; Skotnikov A.S.; Knyazeva S.A.; Rozhnova O.G.; Hamurzova M.A.

doi:https://doi.org/10.17116/kardio201710323-30

Sizova Zh.M.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Skotnikov A.S.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Knyazeva S.A.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Rozhnova O.G.

Comorbidities research center «Rational medicine» Moscow, Russia

Hamurzova M.A.

Municipal polyclinic №6 branch №2 of the Healthcare Department of Moscow, Moscow, Russia

Combined cardioprotection in patients with high cardiovascular risk

Authors:

Sizova Zh.M., Skotnikov A.S., Knyazeva S.A., Rozhnova O.G., Hamurzova M.A.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2017;10(3): 23‑30

DOI: 10.17116/kardio201710323-30

Read: 1730 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Sizova ZhM, Skotnikov AS, Knyazeva SA, Rozhnova OG, Hamurzova MA. Combined cardioprotection in patients with high cardiovascular risk. Russian Journal of Cardiology and Cardiovascular Surgery. 2017;10(3):23‑30. (In Russ.)
https://doi.org/10.17116/kardio201710323-30

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Aim — to determine role of the early appointment of combined cardioprotection on the quality of life and the prognosis of patients after ACS. Tasks — to study the practice of routine use of cardioprotectors in patients after ACS, appointed in the framework of complex therapy of coronary heart disease for the purpose of preventing attacks of angina pectoris; to evaluate the effectiveness of early use of combined cardioprotection for slowing the progression of coronary heart disease and chronic heart failure (CHF); to determine the safety of combined cardioprotection in outpatient settings. Material and metods. The authors observed patients (n=482) with a verified diagnosis of coronary heart disease, not less than 30 days and no more than 90 days ago after ACS with ST segment elevation (n=174) or without it (n=308) with outcome in unstable angina or myocardial infarction; without an anamnesis of post infarction angina and other complications of the post infarction period. Subgroup «A» (n=97) (monotherapy with trimetazidine), subgroup «B» (n=98) (combination of trimetazidine and meldonium) and subgroup «C» (n=74) (combination of trimetazidine and succinate) are further distinguished. Once every 3 months, within 1 year, clinical parameters were evaluated (death from all causes, recurrence of ACS, call for emergency medical care, emergency and planned hospitalization for decompensation of cardiovascular pathology, as well as the number of attacks of angina and its equivalents per week, the cardiac frequency, the level of systolic (SBP) and diastolic (DBP) blood pressure, the presence of signs of heart failure, the need for nitrates). Results. Over 360 days of outpatient observation, the majority of monitored parameters underwent change in the compared groups. None of the observed groups/subgroups of deaths (from any cause) were recorded. Combined cardioprotection with trimetazidine and meldonium during the first year after ACS is more effective than monotherapy with trimetazidine and than combinations of trimetazidine and succinate: with regard to the resumption of angina pectoris by 9.3 (p<0.05) and by 8.0% (p<0.05) respectively; to the number of attacks of angina and its equivalents in the week by 46.9 (p<0.05) and by 34.6% (p<0.05) respectively; with respect to the average amount of nitroglycerin by 34.1 (p<0.05) and by 17.1% (p<0.05) respectively; of development of paroxysms of atrial fibrillation by 21.7 (p<0.05) and 1.3% (p>0.05) respectively; of CHF progression by 3.2 (p>0.05) and by 1.7% (p>0.05) respectively; to the number of hospitalizations for decompensation of cardiovascular pathology by 6.2 (p<0.05) and by 5.4% (p<0.05) respectively; for new cases of ACS by 2.0 (p>0.05) and by 0.3% (p>0.05) respectively.

Keywords:

combined cardioprotection

acute coronary syndrome in the past

ischemic heart disease

comorbidity

meldonium

idrinol

Authors:

Sizova Zh.M.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Skotnikov A.S.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Knyazeva S.A.

I.M. Sechenov First Moscow state medical university, Institute of postgraduate professional education, Department of medical and social expertise, emergency and polyclinic therapy, Moscow, Russia

Rozhnova O.G.

Comorbidities research center «Rational medicine» Moscow, Russia

Hamurzova M.A.

Municipal polyclinic №6 branch №2 of the Healthcare Department of Moscow, Moscow, Russia

Close metadata

References:

ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal. 2013;34:2159-2219. https://doi.org/10.1093/eurheartj/eht151
Ardissino D. Coagulation activation and long term outcome in acute coronary syndromes. Blood. 2003;102:2731-2735. https://doi.org/10.1182/blood-2002-03-0954
Merlini P, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61-68. https://doi.org/10.1161/01.cir.90.1.61
Fogelman AM. From fatty streak to myocardial infarction: an inflammatory response to oxidized lipids. Circulation. 1994;90:I-B.
Hansson GK. Inflammation, injury and atherosclerosis — the Russel Ross memorial lecture. In: Stemme S, Olsson AG, eds. Atherosclerosis XII. Elsvier Science B.V. 2000;53-66.
Farb A, Burke AP, Tang AL, Liang Y, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden death. Circulation. 1996;93:1354-1363. https://doi.org/10.1161/01.cir.93.7.1354
Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44. https://doi.org/10.1161/01.cir.89.1.36
Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol. 2001;38:64-71. https://doi.org/10.1016/s0735-1097(01)01307-9
Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, Skibinska E, Szymczak K, Swiatek J, Winter M. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II) TRIMetazidine in POLand. Eur Heart J. 2001;22:2267-2274. https://doi.org/10.1053/euhj.2001.2896
Makolkin V, Osadchiy K. Trimetazidine modified release in the treatment of stable angina. TRIUMPH Study. Clin Drug Invest. 2004;24:12:731-738. https://doi.org/10.2165/00044011-200424120-00004
Montalescot G, Sechtem U. ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013. https://doi.org/10.1093/eurheartj/ent296
Ponikowski P, Voors AA, Anker SD Héctor Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juanatey J.R., Harjola V-P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-1200. https://doi.org/10.1093/eurheartj/ehw128
Bokeriya LA, Aronov DM. Russian clinical guidelines. Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. Cardifsomatics. 2016;7(3-4):5-71.
Aronov DM, Bubnova MG, Krasnitskiy VB. Novel Approaches to Rehabilitation and Secondary Prevention of Survivors of ST-Elevation Myocardial Infarction. Kardiologiia. 2015;12:125-132. (In Russ.). https://doi.org/10.18565/cardio.2015.12.125-132
Kardiovaskulyarnaya profilaktika. Natsional’nye rekomendatsii. Razrabotany Komitetom ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov. Moskva 2011. Prilozhenie 2 k zhurnalu «Kardiovaskulyarnaya terapiya i profilaktika». 2011;10(6). (In Russ.).
Vinogradov AV, Arutyunov GP, Dmitriev DV. The results of the application of Mildronate in the acute period of myocardial infarction. Eksperimental’naya i klinicheskaya farmakoterapiya. (Riga). 1991;19:135-139. (In Russ.).
Tyurikov PYu, Zueva ON, Sharova VG. Cardioprotective action of the metabolic drug Mildronate. Uspekhi sovremennogo estestvoznaniya. 2004;10:131-132. (In Russ.).
Statsenko ME, Turkina SV, Belenkova SV, Poletaeva LV, Dudchenko GP. Effects of mildronate, as a part of combined heart failure therapy, on carbohydrate nd lipid metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus. Russian Journal of Cadiology. 2010;2:45-51. (In Russ.). https://doi.org/10.15829/1560-4071-2010-2-45-51
Latfoullin IA, Podolskaya AA, Ishmourzin GP. Efficency of mildronate in the acute period of myocardial infraction. Vestnik sovremennoi klinicheskoi meditsiny. 2009;2:4:23a-25 (In Russ.).
Mikhin VP, Chernyatina MA, Panchenko GV, Kharchenko AV, Cukanova YA. Efficiency of Meldonium in the Complex Therapy of Acute Coronary Syndrome. Kardiologiia. 2014;11:11-19. (In Russ.). https://doi.org/10.18565/cardio.2014.11.11-19
Mikhin VP, Kol’tsova ON. The effectiveness of Mildronate on post-hospital stage of rehabilitation of patients after myocardial infarction. Kardiovaskulyarnaya terapiya i profilaktika. 2012;2:57-61. (In Russ.).
Tsvetkova OA, Gracheva EA. Kardionat in the treatment of metabolic syndrome components in adults. RMZh. 2012;14:678-681. (In Russ.).